TRAJENTA® is backed by one of the most unique and robust CVOT programmes across a broad range of T2D patients.

CV outcome trial program
CARMELINA
Blue arrow
  • 6,979 patients at high risk for
    heart disease and/or CKD
  • TRAJENTA® vs placebo
  • 2.2 years median follow-up
CARMELINA
Yellow arrow
  • 6,033 relatively early T2D
    patients at increased CV risk§
  • TRAJENTA® vs glimepiride
  • 6.3 years median follow-up

*The CARMELINA® primary endpoint is time to first occurrence of any of the following components: CV death, non-fatal MI, non-fatal stroke. The key secondary endpoint is time to first occurrence of any of the following components: death due to kidney disease, sustained ESRD or a sustained decrease of ≥40% in eGFR from baseline.

The CAROLINA® primary endpoint is time to first occurrence of any of the following components: CV death, non-fatal MI and non-fatal stroke.

CARMELINA® included patients with albuminuria & previous macrovascular disease, and/or impaired kidney function with or without CV comorbidities.

§CAROLINA® included patients with early type 2 diabetes and at increased CV risk

CKD: Chronic kidney disease; CV: Cardiovascular; CVOT: Cardiovascular outcome trial; eGFR: Estimated glomerular filtration rate; ESRD: End-stage renal disease; MI: Myocardial infarction.

Hear what experts are saying
about these 2 unique
cardiovascular outcome trials

See for yourself the
results of the unique
CVOT CARMELINA®

NEW!
The CAROLINA® results
are now available